The CAR T-cell therapy agents market is booming, projected to reach $376.6 million by 2025 with a 6.7% CAGR. This comprehensive analysis explores market drivers, trends, restraints, key players (Novartis, Gilead, Bristol Myers Squibb), and regional data for CD19 & BCMA targeted therapies in treating lymphoma and multiple myeloma. Discover the future of cancer treatment.

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.